Professional Documents
Culture Documents
Myasthenia Gravis During Pregnancy: Motherisk Update
Myasthenia Gravis During Pregnancy: Motherisk Update
Abstract
Question One of my patients who has been diagnosed with myasthenia gravis (MG) is planning pregnancy. Her
MG is controlled with medications. Can her condition or her medications adversely affect her pregnancy?
Answer The course of MG during pregnancy is unpredictable, but there is no evidence that MG can adversely
affect pregnancy outcomes. Examination of most of the medications used for symptom control has so far shown
reassuring results. Prepregnancy thymectomy might decrease the need for medications during pregnancy. The
newborn should be carefully monitored for signs of transitory MG.
Réponse L’évolution de la MG durant la grossesse est imprévisible, mais il n’existe pas de données probantes à
l’effet que la MG puisse influencer négativement l’issue de la grossesse. Les résultats des études sur la plupart des
médicaments utilisés pour le contrôle des symptômes sont jusqu’à présent rassurants. Une thymectomie avant
la grossesse pourrait réduire la nécessité de prendre des médicaments durant la grossesse. Il faudra surveiller
attentivement le nouveau-né pour détecter tout signe de MG transitoire.
1346 Canadian Family Physician • Le Médecin de famille canadien | Vol 58: DECEMBER • DÉCEMBRE 2012
Motherisk Update
suggested that placental transfer of maternal antibod- teratogenicity in human fetuses.23 It is associated with
ies, not the pyridostigmine, might have caused the fetal first-trimester miscarriage and structural malformations
anomalies.11 Their claim is supported by studies that of the ears and jaw, cleft lip and palate, as well as hypo-
show safe use of pyridostigmine by women with MG plastic fingers and toenails.24-26
during pregnancy.5,8,10 In addition to these drugs, medications that exac-
Corticosteroids such as prednisone and its biolog- erbate symptoms of MG by potentiating the effect of
ically active compound prednisolone are commonly ACh receptor antibodies are contraindicated in patients
used in MG.11 A Motherisk meta-analysis determined an with MG. These drugs include neuromuscular blocking
increased odds ratio (OR) of oral cleft with corticoste- agents (eg, magnesium sulfate), antiarrhythmic drugs
roids (OR = 3.69, 95% CI 2.15 to 6.32). Although the sum- (eg, quinidine), and local anesthetics (eg, esters), as well
mary OR of cohort studies was not significant (OR = 2.74, as antibiotics from the aminoglycoside, quinolone, and
95% CI 0.96 to 7.82), the cohort studies showed a cluster- macrolide classes.27
ing of cleft palate when compared with the controls.12,13
Women with MG who are prescribed corticosteroids Conclusion
must be informed before conception of the increased There is no evidence that MG can adversely affect preg-
risks of oral clefts. It is important to note that the forma- nancy outcomes, and most of the medications used for
tion of the palate is complete in the fetus by week 12.14 symptom control appear to be relatively safe during
Thus, one option is to commence corticosteroid therapy pregnancy (except for MFM, used as second-line ther-
after week 12. apy). Prepregnancy thymectomy might decrease the need
Azathioprine (AZA) has not been associated with for medications during pregnancy. The newborn should
increased rates of congenital abnormalities.15 However, be carefully monitored for signs of transitory MG.
there is evidence of possible intrauterine growth retar- Competing interests
None declared
dation and infants with low birth weight, and concern
References
about immunologic changes.15,16 Despite these reports, it 1. Gilhus NE, Owe JF, Hoff JM, Romi F, Skeie GO, Aarli JA. Myasthenia gravis: a
is difficult to determine whether AZA is the sole cause of review of available treatment approaches. Autoimmune Dis 2011;2011:847393.
Epub 2011 Oct 5.
these adverse outcomes or whether they are due to the 2. Ferrero S, Esposito F, Biamonti M, Bentivoglio G, Ragni N. Myasthenia gravis
underlying maternal condition or to other drugs used during pregnancy. Expert Rev Neurother 2008;8(6):979-88.
3. Ferrero S, Pretta S, Nicoletti A, Petrera P, Ragni N. Myasthenia gravis: man-
in combination with AZA to treat the mother.17 In addi- agement issues during pregnancy. Eur J Obstet Gynecol 2005;121(2):129-38.
tion, initial findings from an ongoing study by Motherisk 4. Buckley C, Douek D, Newsom-Davis J, Vincent A, Willcox N. Mature, long-
lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia
assessing neurodevelopment in children exposed to AZA gravis. Ann Neurol 2001;50(1):64-72.
in utero do not suggest significant effects on IQ com- 5. Djelmis J, Sostarko M, Mayer D, Ivanisevic M. Myasthenia gravis in preg-
nancy: report on 69 cases. Eur J Obstet Gynecol Reprod Biol 2002;104(1):21-5.
pared with unexposed children.18 6. Da Silva FC, do Cima LC, de Sá RAM. Myasthenia gravis and pregnancy. In:
Although cyclosporine has been shown to cross the Minagar A, editor. Neurological disorders and pregnancy. Burlington, MA:
Elsevier; 2011. p. 55-68.
placenta readily, there has been no evidence that it is 7. Berlit S, Tuschy B, Spaich S, Sütterlin M, Schaffelder R. Myasthenia gravis in
associated with increased risk of severe complications pregnancy: a case report. Case Rep Obstet Gynecol 2012;2012:736024. Epub
2012 Jan 26.
or malformations.3,11 A recent Motherisk study found 8. Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis in pregnancy and birth:
identifying risk factors, optimising care. Eur J Neurol 2007;14(1):38-43.
that renal transplant patients who were taking cyclospo-
9. Chieza JT, Fleming I, Parry N, Skelton VA. Maternal myasthenia gravis com-
rine therapy had a higher rate of preterm delivery, which plicated by fetal arthrogryposis multiplex congenita. Int J Obstet Anesth
2011;20(1):79-82. Epub 2010 Nov 26.
was associated with lower birth weight in the neonates 10. Dominovic-Kovacevic A, Ilic T, Vukojevic Z. Myasthenia gravis and preg-
of these women.19 However, assessment of long-term nancy—case report. Curr Top Neurol Psychiatr Relat Discip 2010;18(4):40-3.
11. Briggs G, Freeman R, Yaffe S. Drugs in pregnancy and lactation. Philadelphia,
neurodevelopment outcomes in cyclosporine-exposed PA: Lippincott Williams & Wilkins; 2008.
children did not reveal any significant differences com- 12. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett
L, et al. Birth defects after maternal exposure to corticosteroids: prospec-
pared with unexposed children.19 Hence, cyclosporine tive cohort study and meta-analysis of epidemiological studies. Teratology
therapy can be used during pregnancy in which the ben- 2000;62(6):385-92.
13. Gur C, Diav-Citrin O, Shechtman S, Arnon J, Ornoy, A. Pregnancy outcome
efit to the mother outweighs the risk to the fetus.20,21 after first trimester exposure to corticosteroids: a prospective controlled study.
Rituximab readily crosses the placenta at about 16 Reprod Toxicol 2004;18(1):93-101.
14. Lee S, Sykes J. Cleft lip and palate. In: Stucker FJ, de Souza C, Kenyon GS,
weeks’ gestation.21 To date, there have not been any Lian TS, Draf W, Schick B, editors. Rhinology and facial plastic surgery. New
reports of major malformations attributed to rituximab York, NY: Springer; 2009. p. 909-16.
15. Goldstein LH. Pregnancy outcome of women exposed to azathioprine during
exposure.22 There were some cases of decreased B-cell pregnancy. Birth Defects Res A Clin Mol Teratol 2007;79(10):696-701.
counts in infants born to women using rituximab, but 16. Matalon ST, Ornoy A, Lishner M. Review of the potential effects of three
commonly used antineoplastic and immunosuppressive drugs (cyclophospha-
this condition resolved within 6 months.22 mide, azathioprine, doxorubicin on the embryo and placenta). Reprod Toxicol
2004;18(2):219-30.
Mycophenolate mofetil (MFM) is a second-line drug
17. Polifka JE. Teratogen update: azathioprine and 6-mercaptopurine. Teratology
for treatment of mild forms of MG.1 Recently MFM 2002;65(5):240-6.
18. Teratology Society 51st Annual Meeting, June 25-29, 2011, Coronado,
was reclassified by the Food and Drug Administration California, USA. Abstracts. Birth Defects Res A Clin Mol Teratol
as a class D drug, indicating that there is evidence of 2011;91(5):305-420.
1348 Canadian Family Physician • Le Médecin de famille canadien | Vol 58: DECEMBER • DÉCEMBRE 2012
Motherisk Update